Skip to main content

Dunlop A. Sinclair's Form 4 filing

Apellis Pharmaceuticals, Inc.APLS · filed Sep 19, 2025

Accession no.
0001193125-25-209537
Filed
Sep 19, 2025
Trade date
Sep 19, 2025
Filing delay
Same day
Rule 10b5-1 plan
Checked

This filing lists 2 non-derivative transactions. Open-market sales total $713.6K. It was filed on the trade date.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Dunlop A. SinclairCIK 0001721108Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Sep 19, 2025Common StockSSaleDisposed−31,092$22.95F2−$713,561.468,908Indirect
Sep 19, 2025Common StockJOtherDisposed−3,837$0.00$065,071Indirect

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F2

The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $22.73 to $23.27, inclusive. The reporting person hereby undertakes to provide, upon request, to the staff of the Securities and Exchange Commission, the issuer or a security holder of the issuer full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)